Return to search

Ethnic differences in the pharmacokinetics and pharmacodynamics of ACE-inhibitors between healthy Chinese and Caucasian volunteers.

by Patricia Jane Anderson. / Thesis (M. Phil.)--Chinese University of Hong Kong, 1993. / Includes bibliographical references (leaves 199-215). / List of Figures --- p.i / List of Tables --- p.v / List of Abbreviations --- p.viii / Abstract --- p.1 / Introduction --- p.3 / Chapter Chapter 1 - --- Literature Reviews / Chapter 1.1 --- Pharmacoanthropology and Pharmacogenetics --- p.5 / Chapter 1.1.1 --- Genetic Polymorphisms --- p.7 / Chapter 1.1.2 --- Pharmacogenetics in Asians and Caucasians --- p.13 / Chapter 1.1.2.1 --- ACE-inhibitors in Asians and Caucasians --- p.18 / Chapter 1.2 --- The Renin Angiotensin System --- p.20 / Chapter 1.2.1 --- Discovery of Inhibitors of Angiotensin Converting Enzyme --- p.24 / Chapter 1.3 --- ACE-Inhibiting Drugs --- p.25 / Chapter 1.3.1 --- Pharmacokinetics and Pharmacodynamics of Perindopril --- p.28 / Chapter 1.3.2 --- The Pharmacokinetics and Pharmacodynamics of Cilazapril --- p.32 / Chapter Chapter 2 - --- General Methodology / Chapter 2.1 --- Introduction --- p.38 / Chapter 2.2 --- Subjects --- p.49 / Chapter 2.3 --- Sample Collection --- p.40 / Chapter 2.3.1 --- Blood Samples --- p.40 / Chapter 2.3.2 --- Urine Samples --- p.40 / Chapter 2.4 --- Blood Pressure and Heart Rate Measurements --- p.41 / Chapter 2.5 --- Measurement of Transthoracic Electrical Bioimpedance --- p.41 / Chapter 2.5.1 --- Background --- p.42 / Chapter 2.5.2 --- Practical Details --- p.45 / Chapter 2.6 --- Data Analysis --- p.48 / Chapter 2.6.1. --- Analysis of Pharmacokinetic Parameters --- p.48 / Chapter 2.6.2 --- Analysis of Pharmacodynamic Parameters --- p.59 / Chapter 2.6.3 --- Analysis of Non-Invasive Haemodynamic Monitoring Data --- p.60 / Chapter 2.7 --- Statistical Analysis --- p.64 / Chapter Chapter 3 - --- The Perindopril Study / Chapter 3.1 --- Introduction --- p.67 / Chapter 3.1.1 --- Aims --- p.67 / Chapter 3.2 --- Methodology --- p.68 / Chapter 3.2.1 --- Inclusion Criteria --- p.68 / Chapter 3.2.2 --- Non-Inclusion Criteria --- p.69 / Chapter 3.2.3 --- Study Design --- p.69 / Chapter 3.2.4 --- Blood Sampling --- p.71 / Chapter 3.2.5 --- Urine Sampling --- p.71 / Chapter 3.2.6 --- Blood Pressure and Heart Rate --- p.72 / Chapter 3.2.7 --- Non-invasive Haemodynamic Monitoring --- p.72 / Chapter 3.2.8 --- Analysis of Plasma Samples --- p.73 / Chapter 3.2.9 --- Hormone and Enzyme Assays --- p.74 / Chapter 3.3 --- Data Analysis and Statistical Methods --- p.75 / Chapter 3.3.1 --- Pharmacokinetic Analysis of Plasma --- p.75 / Chapter 3.3.2 --- Pharmacokinetic Analysis of Urine --- p.75 / Chapter 3.3.3 --- Pharmacodynamic Analysis of Hormone Data --- p.75 / Chapter 3.3.4 --- Analysis of Haemodynamic Monitoring Data --- p.76 / Chapter 3.3.5 --- Statistical Analysis --- p.76 / Chapter 3.4 --- Pharmacokinetic Results --- p.77 / Chapter 3.4.1 --- Pharmacokinetics of Perindopril in Plasma --- p.77 / Chapter 3.4.2 --- Pharmacokinetics of Perindopril in Urine --- p.84 / Chapter 3.4.3. --- Pharmacokinetics of Perindoprilat in Plasma --- p.85 / Chapter 3.4.4 --- Pharmacokinetics of Perindoprilat in Urine --- p.89 / Chapter 3.5 --- Pharmacodynamic Results --- p.89 / Chapter 3.5.1 --- Angiotensin Converting Enzyme Inhibition --- p.89 / Chapter 3.5.2 --- Angiotensin I (AI) --- p.102 / Chapter 3.5.3 --- Aldosterone and Plasma Renin Activity (PRA) --- p.102 / Chapter 3.5.4 --- Plasma Protein Binding --- p.102 / Chapter 3.5.5 --- Blood Pressure and Heart Rate --- p.107 / Chapter 3.5.6. --- Safety and Tolerance --- p.108 / Chapter 3.5.7 --- Non-invasive Haemodynamic Monitoring --- p.108 / Chapter 3.6 --- Discussion --- p.120 / Chapter Chapter 4 - --- The Cilazapril Study / Chapter 4.1 --- Introduction --- p.135 / Chapter 4.1.1 --- Aims --- p.135 / Chapter 4.2 --- Methodology --- p.136 / Chapter 4.2.1 --- Inclusion Criteria --- p.136 / Chapter 4.2.2. --- Exclusion Criteria --- p.136 / Chapter 4.2.3 --- Study Design --- p.137 / Chapter 4.2.4 --- Blood Sampling --- p.139 / Chapter 4.2.5 --- Urine Sampling --- p.140 / Chapter 4.2.6 --- Blood Pressure and Heart Rate --- p.140 / Chapter 4.2.7 --- Non-Invasive Haemodynamic Monitoring --- p.140 / Chapter 4.2.8 --- Analysis of Plasma Cilazaprilat Samples --- p.142 / Chapter 4.2.9 --- Hormone and Enzyme Assays --- p.143 / Chapter 4.3 --- Data Analysis and Statistical Methods --- p.143 / Chapter 4.3.1 --- Pharmacokinetic Analysis --- p.143 / Chapter 4.3.2 --- Pharmacodynamic Analysis of Hormone Data --- p.144 / Chapter 4.3.3 --- Analysis of Non-Invasive Haemodynamic Monitoring Data --- p.144 / Chapter 4.3.4 --- Statistical Analysis --- p.146 / Chapter 4.4 --- Pharmacokinetic Results --- p.146 / Chapter 4.4.1 --- Pharmacokinetics of Cilazaprilat in Plasma --- p.146 / Chapter 4.5 --- Pharmacodynamic Results --- p.150 / Chapter 4.5.1 --- Angiotensin Converting Enzyme Inhibition --- p.150 / Chapter 4.5.2 --- Aldosterone and Plasma Renin Activity (PRA) --- p.155 / Chapter 4.5.3 --- Blood Pressure and Heart Rate --- p.155 / Chapter 4.5.4 --- Safety and Tolerance --- p.159 / Chapter 4.5.5 --- Non-Invasive Haemodynamic Monitoring --- p.160 / Chapter 4.6 --- Discussion --- p.182 / Chapter Chapter 5 - --- General Discussion --- p.188 / Appendix --- p.195 / References --- p.199 / Acknowledgements --- p.216

Identiferoai:union.ndltd.org:cuhk.edu.hk/oai:cuhk-dr:cuhk_319246
Date January 1993
ContributorsAnderson, Patricia Jane., Chinese University of Hong Kong Graduate School. Division of Clinical and Pathological Sciences.
PublisherChinese University of Hong Kong
Source SetsThe Chinese University of Hong Kong
LanguageEnglish
Detected LanguageEnglish
TypeText, bibliography
Formatprint, x, 216 leaves : ill. (some col.) ; 30 cm.
RightsUse of this resource is governed by the terms and conditions of the Creative Commons “Attribution-NonCommercial-NoDerivatives 4.0 International” License (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Page generated in 0.0024 seconds